Should You Buy Cardiff Oncology Inc (CRDF) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a Beginner, long-term investor with $50k–$100k who is impatient. The stock is in a sharp downtrend after leadership resignations and remains a high-uncertainty small-cap biotech despite encouraging trial updates and bullish analysts. I would avoid initiating a new position today; only consider it if you intentionally want a high-risk, event-driven biotech speculation.
Technical Analysis
Price/Trend: CRDF is in a steep short-term downtrend (regular session -17.25% with a larger drop following the CEO/CFO resignation headline). Momentum: MACD histogram is negative (-0.136) and expanding lower, signaling bearish momentum is still building. Overbought/oversold: RSI(6) at 12.06 is extremely oversold, which increases the odds of a short-term bounce, but does not confirm a trend reversal. Levels: Key supports are near S2=1.58 (very close to current ~1.655) and S1=1.913 (now overhead resistance after the breakdown). Pivot resistance sits much higher at 2.452. Takeaway: technically this looks like a falling knife with “oversold bounce” potential, not a stabilized long-term entry.
Analyst Ratings and Price Target Trends
Recent trend: analyst tone is decisively bullish despite the selloff. (1) 2026-01-28 H.C. Wainwright reiterated Buy and called the selloff an overreaction; PT $10. (2) 2026-01-05 Noble initiated Outperform; PT $12. Wall Street pros view (pros): encouraging clinical update and clear upcoming catalyst window (more mature data in 1H 2026), plus the drop creates large upside-to-target if execution continues. Cons: leadership turnover adds execution risk at a critical time, and the stock’s move shows fragile confidence—these targets rely heavily on clinical/regulatory success rather than current fundamentals. Politicians/influential figures: no recent Congress trading data available; hedge funds are described as neutral.
Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 13.67 USD with a low forecast of 10 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 13.67 USD with a low forecast of 10 USD and a high forecast of 19 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 1.620
Current: 1.620
